Personalized medicine: paradigm shift in ALK positive non-small cell lung cancer: a case report

Journal of Medical Case Reports - Tập 17 Số 1
João Vasco Barreira1, José Leão Mendes2, Anuraj Parmanande3
1CUF Oncologia, Lisboa, Portugal
2Centro Hospitalar Universitário Lisboa Central, Lisboa, Portugal
3Hospital SAMS, Lisboa, Portugal

Tóm tắt

Abstract Background Since the identification of multiple therapeutic targets, as is the case of anaplastic lymphoma kinase (ALK) translocation, the paradigm of treating patients with non-small cell lung cancer (NSCLC) has improved. In order to guarantee the possibility of longer survival outcomes with a better quality of life we must invest in the determination, in suitable time, of the consensual biomarkers and in the availability of the best treatments to our patients. Case presentation We present a case of a caucasian male in his fifth decade of life, non-smoker, who highlights the complex journey of ALK-positive patients. This particular case, demonstrates the efficacy and tolerability of the new ALK target therapies, allowing our patients to maintain their routines without compromising the effectiveness of the therapy. Conclusion Focusing on the reality of ALK positive patients and the impact that this therapy has on the daily lives of our patients, we can contribute to the awareness of this specific pathology.

Từ khóa


Tài liệu tham khảo

Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535–54. https://doi.org/10.1016/S0140-6736(21)00312-3.

Korpanty GJ, Kamel-Reid S, Pintilie M, et al. Lung cancer in never smokers from the Princess Margaret Cancer Centre. Oncotarget. 2018;9(32):22559–70. https://doi.org/10.18632/oncotarget.25176.

Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339–57. https://doi.org/10.1016/j.annonc.2022.12.009.

Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 2009;4(12):1450–4. https://doi.org/10.1097/JTO.0b013e3181c4dedb.

Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer. 2018;17(1):52. https://doi.org/10.1186/s12943-018-0810-4.

Kerr KM, Bibeau F, Thunnissen E, et al. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer. 2021;154:161–75. https://doi.org/10.1016/j.lungcan.2021.02.026.

Toyokawa G, Seto T, Takenoyama M, Ichinose Y. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev. 2015;34(4):797–805. https://doi.org/10.1007/s10555-015-9592-y.

Gitlitz BJ, Novello S, Vavalà T, Bittoni M, Sable-Hunt A, Pavlick D, Hsu R, Park SL, Chen R, Cooke M, Moore A, Schrock AB, Schiller JH, Addario BJ, Oxnard GR. The genomics of young lung cancer: comprehensive tissue genomic analysis in patients under 40 with lung cancer. JTO Clin Res Rep. 2021;2(7):100194. https://doi.org/10.1016/j.jtocrr.2021.100194.

Peng L, Zhu L, Sun Y, et al. Targeting ALK rearrangements in NSCLC: current state of the art. Front Oncol. 2022;12:863461. https://doi.org/10.3389/fonc.2022.863461.

Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829–38. https://doi.org/10.1056/NEJMoa1704795.

Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial [published correction appears in J Thorac Oncol. 2022 Oct 14;:]. J Thorac Oncol. 2021;16(12):2091–108. https://doi.org/10.1016/j.jtho.2021.07.035.

Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018–29. https://doi.org/10.1056/NEJMoa2027187.

Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874–86. https://doi.org/10.1016/S1470-2045(17)30339-X.

Schmid S, Cheng S, Chotai S, et al. Real-world treatment sequencing, toxicities, health utilities, and survival outcomes in patients with advanced ALK-rearranged non-small-cell lung cancer. Clin Lung Cancer. 2023;24(1):40–50. https://doi.org/10.1016/j.cllc.2022.09.007.

Thông tin
Thông tin xuất bản

Journal of Medical Case Reports

Tập 17 Số 1

Thông tin tác giả